Suprachoroidal Drug Delivery for Uveitic Macular Edema

In this interview from AAO 2018, Dr. Rahul Khurana provides an update on the safety and efficacy of suprachoroidal drug delivery to manage uveitic macular edema. Participants in the PEACHTREE trial received either suprachoroidal steroid or sham injection at months 1 and 3. Approximately half of patients in the treatment group gained 3 or more lines of vision and demonstrated resolution of macular edema. More than two-thirds of participants had resolution of their uveitic inflammation. The rate of adverse events associated with suprachoroidal steroids was low. Although there are other available therapies, Dr. Khurana explains that suprachoroidal drug delivery may be a safer and more effective treatment for patients with uveitic macular edema.

Relevant Financial Disclosures: Dr. Khurana receives grant support from Clearside Biomedical